Unfortunately, mutational analysis of KRAS and NRAS genes was not performed for all collected NSCLC samples, and thus we could not evaluate ALK and ROS1 expression in RAS‐positive cases, which is a limitation for this study. This evidence concerns the gene NRAS and non-small cell lung carcinoma.